Trials / Terminated
TerminatedNCT01898273
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Cellectar Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | I-124-CLR1404 | single-dose, intravenous |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2015-09-01
- Completion
- 2015-12-01
- First posted
- 2013-07-12
- Last updated
- 2015-09-09
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01898273. Inclusion in this directory is not an endorsement.